HUE050070T2 - Új immunterápia többféle vérképzõszervi daganat, különösen krónikus limfoid leukémia (CLL) ellen - Google Patents

Új immunterápia többféle vérképzõszervi daganat, különösen krónikus limfoid leukémia (CLL) ellen

Info

Publication number
HUE050070T2
HUE050070T2 HUE15730135A HUE15730135A HUE050070T2 HU E050070 T2 HUE050070 T2 HU E050070T2 HU E15730135 A HUE15730135 A HU E15730135A HU E15730135 A HUE15730135 A HU E15730135A HU E050070 T2 HUE050070 T2 HU E050070T2
Authority
HU
Hungary
Prior art keywords
cll
blood
lymphoid leukemia
against several
chronic lymphoid
Prior art date
Application number
HUE15730135A
Other languages
English (en)
Hungarian (hu)
Inventor
Juliane Stickel
Daniel Kowalewski
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of HUE050070T2 publication Critical patent/HUE050070T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE15730135A 2014-06-20 2015-06-17 Új immunterápia többféle vérképzõszervi daganat, különösen krónikus limfoid leukémia (CLL) ellen HUE050070T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014849P 2014-06-20 2014-06-20
GBGB1411037.3A GB201411037D0 (en) 2014-06-20 2014-06-20 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)

Publications (1)

Publication Number Publication Date
HUE050070T2 true HUE050070T2 (hu) 2020-11-30

Family

ID=51409910

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15730135A HUE050070T2 (hu) 2014-06-20 2015-06-17 Új immunterápia többféle vérképzõszervi daganat, különösen krónikus limfoid leukémia (CLL) ellen

Country Status (14)

Country Link
EP (2) EP3708185A3 (cg-RX-API-DMAC7.html)
JP (1) JP6560261B2 (cg-RX-API-DMAC7.html)
CA (1) CA2950827A1 (cg-RX-API-DMAC7.html)
DK (1) DK3157549T3 (cg-RX-API-DMAC7.html)
ES (1) ES2802155T3 (cg-RX-API-DMAC7.html)
GB (1) GB201411037D0 (cg-RX-API-DMAC7.html)
HU (1) HUE050070T2 (cg-RX-API-DMAC7.html)
LT (1) LT3157549T (cg-RX-API-DMAC7.html)
PL (1) PL3157549T3 (cg-RX-API-DMAC7.html)
PT (1) PT3157549T (cg-RX-API-DMAC7.html)
RS (1) RS60592B1 (cg-RX-API-DMAC7.html)
SI (1) SI3157549T1 (cg-RX-API-DMAC7.html)
TW (3) TWI670282B (cg-RX-API-DMAC7.html)
WO (1) WO2015193359A2 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
US11634470B2 (en) 2015-10-23 2023-04-25 Jai Prakash Integrin binding peptides and uses thereof
EP3389630B1 (en) 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
GB201602918D0 (en) * 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA55153A (fr) 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
MA54832A (fr) 2016-03-01 2021-12-01 Immatics Biotechnologies Gmbh Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
CR20200607A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551)
BR112018070873A2 (pt) * 2016-04-21 2019-02-05 Immatics Biotechnologies Gmbh imunoterapia contra melanoma e outros cânceres
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN107602682A (zh) * 2016-07-07 2018-01-19 胡国田 一种多肽及其应用
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
BR112019021094A2 (pt) 2017-04-10 2020-05-12 Immatics Biotechnologies Gmbh Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres
TW201841937A (zh) 2017-04-10 2018-12-01 德商英麥提克生物技術股份有限公司 用於白血病和其他癌症免疫治療的新穎肽和肽組合物
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
WO2020035123A1 (en) * 2018-08-11 2020-02-20 Baerlecken Niklas Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis
CN109593125A (zh) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
BR7908410A (pt) 1978-12-22 1980-09-09 Biogen Nv Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
WO1997026328A1 (en) 1996-01-17 1997-07-24 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CA2404489A1 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
CN101712721A (zh) 2000-06-05 2010-05-26 阿尔托生物科学有限公司 T细胞受体融合物及共轭物以及其使用方法
AU2002218269A1 (en) * 2000-11-15 2002-05-27 Apoxis Sa Proteins and dna sequences underlying these proteins used for treating inflammations
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DK1766412T3 (da) * 2004-05-21 2009-05-25 Inst Systems Biology Sammensætninger og fremgangsmåder til kvantificering af serumglycoproteiner
SI1806359T1 (sl) 2005-09-05 2010-06-30 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi ki se vežejo brez izjeme na molekule humanega levkocitnega antigena HLA razred II
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors

Also Published As

Publication number Publication date
TWI670282B (zh) 2019-09-01
LT3157549T (lt) 2020-08-10
EP3708185A3 (en) 2020-11-04
JP2017525336A (ja) 2017-09-07
CA2950827A1 (en) 2015-12-23
WO2015193359A3 (en) 2016-02-25
TW201930347A (zh) 2019-08-01
SI3157549T1 (sl) 2020-08-31
TW202024125A (zh) 2020-07-01
PL3157549T3 (pl) 2020-12-14
ES2802155T3 (es) 2021-01-15
EP3157549A2 (en) 2017-04-26
PT3157549T (pt) 2020-07-01
RS60592B1 (sr) 2020-08-31
TW201613956A (en) 2016-04-16
EP3157549B1 (en) 2020-04-29
EP3708185A2 (en) 2020-09-16
GB201411037D0 (en) 2014-08-06
DK3157549T3 (da) 2020-06-22
WO2015193359A2 (en) 2015-12-23
JP6560261B2 (ja) 2019-08-14

Similar Documents

Publication Publication Date Title
SI3157549T1 (sl) Nova imunoterapija proti številnim krvnim tumorjem, zlasti kronični limfoidni levkemiji (CLL)
ZA202005298B (en) Combination tumor immunotherapy
DK3140319T3 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
IL243788A0 (en) New immunotherapy against various tumors such as lung cancer which includes nsclc
EP3094342A4 (en) Anti-tumor therapy
GB201507030D0 (en) Immunotherapy against lung cancers, in particular NSCLC
IL252053A0 (en) Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
IL295031B1 (en) Innovative immunotherapy against several tumors, such as lung cancer, including nsclc
EP3098540A4 (en) Heat pump apparatus
EP3157553A4 (en) Treatment for chronic lymphocytic leukemia (cll)
EP3152579A4 (en) Molecular mammography
EP3204001A4 (en) Avocado-derived lipids for use in treating leukemia
IL271367A (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
IL249533A0 (en) Treatment of chronic lymphocytic leukemia
GB201403297D0 (en) Novel immunotherapy against several tumors, such as lung cancer, including NSCLC
GB201313987D0 (en) Novel immunotherapy against several tumors, such as lung cancer including NSCLC
GB201519261D0 (en) Novel Immunotherapeutic treatments for tumours
TWM490263U (en) Adjustable table